Omeros Corporation (NASDAQ:OMER) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.
Latest reports show that Omeros Corporation has closed a deal worth around $2.1 billion with drug giant Novo Nordisk for the zaltenibart, a phase 2 asset of the former, in development for rare blood and kidney disorders. Omeros is receiving $340 million in upfront and near-term milestone payments, up to $2.1 billion in milestone payments, plus tiered royalties on potential net sales.
Omeros Corporation continues to receive bullish reviews from analysts on Wall Street. HC Wainwright has a Buy rating on the shares with a price target of $9. The company’s lead product candidate is the Narsoplimab for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy. It also develops OMS1029, which has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 and lectin pathway disorders.
Omeros Corporation is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term
